Trend. Only 4.30% of the stock of BioCryst Pharmaceuticals is held by insiders. BCRX Stock Analysis - [Full Report] Free Signup: Advanced stock screener. (Add your “outperform” vote. 326 E 8th St #105, Sioux Falls, SD 57103 | [email protected] | (844) 978-6257 100% FREE. BioCryst Pharmaceuticals is headquartered at 4505 EMPEROR BOULEVARD SUITE 200, DURHAM NC, 27703. Find the latest BioCryst Pharmaceuticals, Inc. (BCRX) stock quote, history, news and other vital information to help you with your stock trading and investing. The official website for BioCryst Pharmaceuticals is www.biocryst.com. Morningstar: © 2019 Morningstar, Inc. All Rights Reserved. Feb 25 / MotleyFool.com - Paid Partner Content, Feb 25 / Zacks.com - Paid Partner Content, Feb 18 / Zacks.com - Paid Partner Content, Why BioCryst Pharmaceuticals Stock Is Falling Today, BioCryst Pharmaceuticals (BCRX) Reports Q4 Loss, Misses Revenue Estimates, BioCryst Pharmaceuticals (BCRX) Q4 2020 Earnings Call Transcript, Analysts Estimate BioCryst Pharmaceuticals (BCRX) to Report a Decline in Earnings: What to Look Out for, This NYC Startup Raises $51M to Disrupt the Retirement Industry, 5 Social Security Mistakes to Avoid At All Costs, 7 Mistakes That Will Ruin Your Retirement Income, 7 Retirement Secrets Smart Americans Should Know, You Can Still Buy This "Millionaire Maker" Stock, Bitcoin Up 30,000X -- Here's Your Backdoor In, This Stock Could Be Like Buying Amazon for $3.19. The BioCryst Pharmaceuticals stock price fell by -2.95% on the last day (Monday, 22nd Feb 2021) from $11.53 to $11.19. Specifically, they have bought $0.00 in company stock and sold $194,985.00 in company stock. Some of MarketBeat's past winning trading ideas have resulted in 5-15% weekly gains. BCRX stock was sold by a variety of institutional investors in the last quarter, including Ghost Tree Capital LLC, Credit Suisse AG, Victory Capital Management Inc., Barclays PLC, Pura Vida Investments LLC, SG Americas Securities LLC, Edge Wealth Management LLC, and Formidable Asset Management LLC. BioCryst Pharmaceuticals' management team includes the following people: The cryptocurrency market is exploding in value right now… Bitcoin broke through $30,000…. Biocryst Pharmaceuticals Inc. (BCRX) Stock Price has been Trending Strongly with an ADX reading of 48.22 as per the Weekly Chart. The … … Investors need to pay close attention to BioCryst (BCRX) stock based on the movements in the options market lately. You may vote once every thirty days. Fundamental company data provided by Zacks Investment Research. The consensus among Wall Street research analysts is that investors should "buy" BioCryst Pharmaceuticals stock. View live BIOCRYST PHARMACEUTICALS INC chart to track its stock's price action. View today's stock price, news and analysis for BioCryst Pharmaceuticals Inc. (BCRX). Since then, BCRX shares have increased by 316.2% and is now trading at $10.78. BCRX Stock Analysis Overview What this means: Biocryst Pharma Inc (BCRX) gets an Overall Rank of 66, which is an above average rank under InvestorsObserver's stock ranking system. Pinterest . Some companies that are related to BioCryst Pharmaceuticals include Amgen (AMGN), Gilead Sciences (GILD), Vertex Pharmaceuticals (VRTX), Regeneron Pharmaceuticals (REGN), Biogen (BIIB), Alexion Pharmaceuticals (ALXN), Seagen (SGEN), Exact Sciences (EXAS), Alnylam Pharmaceuticals (ALNY), Incyte (INCY), Novavax (NVAX), BioMarin Pharmaceutical (BMRN), Repligen (RGEN), Neurocrine Biosciences (NBIX) and United Therapeutics (UTHR). Most Recent Rating. View our earnings forecast for BioCryst Pharmaceuticals. Find the latest analyst research for BioCryst Pharmaceuticals, Inc. Common Stock (BCRX) at Nasdaq.com. All times are ET. Market indices are shown in real time, except for the DJIA, which is delayed by two minutes. All rights reserved. BCRX is higher by $0.61 from the previous closing price of $7.65 on volume of 5,929,634 shares. Date Range. BCRX … Company insiders that own BioCryst Pharmaceuticals stock include Alane P Barnes, Anthony Doyle, Jon P Stonehouse, Kenneth B Lee Jr, Megan Sniecinski, Steve Aselage and Thomas R Staab II. According to . MarketBeat's community ratings are surveys of what our community members think about BioCryst Pharmaceuticals and other stocks. All Rights Reserved. BioCryst Pharmaceuticals Stock Forecast NASDAQ:BCRX Price Target and Analyst Ratings. In the short term (2weeks), BCRX's stock price should underperform the market by -0.19%.During that period the price should oscillate between -10.74% and +13.37%. To see all exchange delays and terms of use please see disclaimer. Dividend. Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: You have already added five stocks to your watchlist. 10 equities research analysts have issued 1-year price targets for BioCryst Pharmaceuticals' stock. Post-Market 0.16 (1.36%) The Barchart Technical Opinion rating is a 100% Buy and ranks in the Top 1% of all short term signal directions. This suggests that the stock has a possible downside of 0.6%. Limited Time Only. To hit the forecast high, the stock’s price needs a +50.23% upsurge from its latest level, while the stock would need to tank -15.49% for it to hit the projected low. MarketBeat All Access subscribers can access stock screeners, the Idea Engine, data export tools, research reports, and other premium tools. The trading price of BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX) floating lower at last check on Monday, Jan 11, closing at $7.74, -3.26% lower than its previous close. Bullish. Date Rating Action Authority Current Price Target Price; 2021-01-22 : Sector Perform: Target Raised by: … All rights reserved. BioCryst Pharmaceuticals Inc. (BCRX) Analyst Forecasts. If compared to the average trading volume of 6.89M shares, BCRX reached a trading volume of 36828873 in the most recent trading day, which is why market watchdogs consider the stock to be active. BCRX Analyst Forecast > Blogger Opinions. Here is what top equities market gurus are saying about BioCryst Pharmaceuticals Inc. [BCRX]: Based … The BioCryst stock analysis is based on the TipRanks Smart Score which is derived from 8 unique data sets including Analyst recommendations, ... BCRX Analyst Forecast > Blogger Opinions. Find the latest Earnings Report Date for BioCryst Pharmaceuticals, Inc. Common Stock (BCRX) at Nasdaq.com. From InvestorPlace; From the Web; BioCryst Pharma News: Why BCRX Stock Is Soaring Today. Forecast Cash Runway: BCRX is forecast to have sufficient cash runway for 9 months based on free cash flow estimates, but has since raised additional capital. 8 Wall Street analysts that have issued a 1 year BCRX price target, the average BCRX price target is $10.63, with the highest BCRX stock price forecast at $14.00 and the lowest BCRX stock price forecast at $7.00. The company was founded in 1986 and is headquartered in Durham, NC. IonutCiuchi. BCRX | Complete BioCryst Pharmaceuticals Inc. stock news by MarketWatch. BioCryst Pharmaceuticals' mailing address is 4505 EMPEROR BOULEVARD SUITE 200, DURHAM NC, 27703. sentiment. Get the latest Baudax Bio, Inc. BXRX detailed stock quotes, stock data, Real-Time ECN, charts, stats and more. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab. Get the latest Detailed Estimate from Zacks Investment Research. All rights reserved. Next Steps Explore more healthy companies in the Pharmaceuticals & Biotech industry. Analyst recommendations provided by FactSet shows that the consensus forecast for BioCryst Pharmaceuticals Inc. (BCRX) is a “Buy”. BCRX, 240. BCRX Stock Analysis - [Full Report] Free Signup: Advanced stock screener. BCRX Stock Forecast. It is based on a 60-month historical regression of the return on the stock onto the return on the S&P 500. Biocryst Pharmaceuticals (BCRX) stock price prediction is 15.246632 USD. sector. BCRX: 11.81 (+6.49%) More news for this symbol. Get the hottest … BioCryst Pharmaceuticals' stock is owned by many different retail and institutional investors. One share of BCRX stock can currently be purchased for approximately $10.78. When the symbol you want to add appears, add it to My Quotes by selecting it and pressing Enter/Return. 70. Most stock quote data provided by BATS. Please log in to your account or sign up in order to add this asset to your watchlist. BioCryst Pharmaceuticals, Inc. (BCRX) stock is higher by 7.97% while the S&P 500 has fallen -0.65% as of 1:16 PM on Friday, Dec 11. bcrx stock forecast for the next 10 days by pretiming. Find out now with a free analysis on BioCryst Pharmaceuticals. To hit the forecast high, the stock’s price needs a +50.23% upsurge from its latest level, while the stock would need to tank -15.49% for it to hit the projected low. BioCryst Pharmaceuticals Inc. (BCRX) Analyst Forecasts. Upgrade to MarketBeat Daily Premium to add more stocks to your watchlist. BCRX. BCRX forecasts Videos only. Scan for strong stocks. On January 22, 2021 "Royal Bank of Canada" gave "Sector Perform" rating for BCRX. Strong buy . Notifications > RSS.feed pretiming (Go to RSS.feed) > Pretiming analysis will be updated one by one at GMT 0:00 everyday > Please read a guide how to use pretiming analysis. st0nkz Last visit Follow Following Unfollow. Export data to Excel for your own analysis. All content of the Dow Jones branded indices © S&P Dow Jones Indices LLC 2019 and/or its affiliates. According to the market data, Biocryst Pharmaceuticals Inc. (BCRX) stock price is $9.79 and the 52 weeks low is $1.6, which means the Biocryst Pharmaceuticals Inc. stock price is up 224.92% in the last 12 months. Date Range. During the day the stock fluctuated 12.21% from a day low at $11.06 to a day high of $12.41. View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. As a bonus to opt-ing into our email newsletters, you will also get a free subscription to the Liberty Through Wealth e-newsletter. View real-time stock prices and stock quotes for a full financial overview. Free Signup : Top 50 Stocks Top 10 Penny Stocks Bullish Engulfing Scanner … Based on aggregate information from My MarketBeat watchlists, some companies that other BioCryst Pharmaceuticals investors own include Inovio Pharmaceuticals (INO), El Pollo Loco (LOCO), Advanced Micro Devices (AMD), Idera Pharmaceuticals (IDRA), OPKO Health (OPK), Dynavax Technologies (DVAX), La Jolla Pharmaceutical (LJPC), Novavax (NVAX), Sorrento Therapeutics (SRNE) and VBI Vaccines (VBIV). Next Steps. Given the current short-term trend, the stock is expected to rise 70.09% during the … View analyst ratings for BioCryst Pharmaceuticals or view top-rated stocks. Learn everything you need to know about successful options trading with this three-part video course. On the technical side, indicators suggest BCRX has a 50% Buy on average for the short term. Limited Time Only. On average, they expect BioCryst Pharmaceuticals' share price to reach $10.71 in the next year. The biotechnology company earns $-108,900,000.00 in net income (profit) each year or ($0.94) on an earnings per share basis. 8 Wall Street analysts that have issued a 1 year BCRX price target, the average BCRX price target is $10.63, with the highest BCRX stock price forecast at $14.00 and the lowest BCRX stock price forecast at $7.00. View which stocks have been most impacted by COVID-19. Feb 24, 2021. Its drug candidates include Berotralstat, BCX9930, BCX9250, RAPIVAB, ALPIVAB, RAPIACTA, PERAMIFLU, Galidesivir and Mundesine. Miguel Garrison - January 11, 2021. Top institutional investors include BlackRock Inc. (9.21%), Northern Trust Corp (1.17%), Nuveen Asset Management LLC (0.94%), Renaissance Technologies LLC (0.73%), Charles Schwab Investment Management Inc. (0.66%) and Voloridge Investment Management LLC (0.59%). bcrx stock forecast for the next 10 days by pretiming ... Stock market timing forecast for the next 10 days, 10 weeks. Learn more. On the other hand, looking at the outlook for the BCRX stock, short term indicators assign the stock an average of 100% Buy, while medium term indicators assign it an average of 100% Buy. Should I buy or sell BCRX? BioCryst climbs after FDA approval for Rapivab in infants, BioCryst Announces FDA Approval of Supplemental New Drug Application for RAPIVAB® Expanding Patient Population to Include Children Six Months and Older, BioCryst Pharmaceuticals Reaches Analyst Target Price, The GameStop frenzy convinced more people to search 'how to buy stocks' than last year's surge, view top-rated stocks among Wall Street analysts, Receive Analysts' Upgrades and Downgrades Daily. Top authors: BCRX. BioCryst Pharmaceuticals, Inc. (BCRX) stock price forecast. By 4.47M Shares Last Quarter. 60-Month Beta: Coefficient that measures the volatility of a stock's returns relative to the market (S&P 500). Wall Street analysts have given BioCryst Pharmaceuticals a "Buy" rating, but there may be better short-term opportunities in the market. report type. Standard & Poor's and S&P are registered trademarks of Standard & Poor's Financial Services LLC and Dow Jones is a registered trademark of Dow Jones Trademark Holdings LLC. Find real-time BCRX - BioCryst Pharmaceuticals Inc stock quotes, company profile, news and forecasts from CNN Business. View all of BCRX's competitors. ), BioCryst Pharmaceuticals has received 408 “underperform” votes. 0. pretiming Stock market timing forecast for the next 10 days, 10 weeks. Find real-time BLRX - BioLine RX Ltd stock quotes, company profile, news and forecasts from CNN Business. View our full suite of financial calendars and market data tables, all for free. 100% FREE. According to analyst projections, BCRX’s forecast low is $9 with $16 as the target high. View BioCryst Pharmaceuticals, Inc. BCRX investment & stock information. investment rating Decreased. Trend. The price has risen in 6 of the last 10 … Get today's BioCryst Pharmaceuticals Inc stock price and latest BCRX news as well as BioCryst real-time stock quotes, technical analysis, full financials and more. BioCryst Pharmaceuticals trades on the NASDAQ under the ticker symbol "BCRX.". Price/Sales: Latest closing price divided by the last 12 months of revenue/sales per share. BCRX stock forecast Our latest prediction for Biocryst Pharmaceuticals Inc.'s stock price was made on the Aug. 11, 2020 when the stock price was at 3.96$.. View insider buying and selling activity for BioCryst Pharmaceuticals or or view top insider-buying stocks. As a result, BCRX is trading at a discount of 35.48% off the target high and -23.79% off the low. View real-time stock prices and stock quotes for a full financial overview. Twitter. Barchart Technical Opinion . Receive a free world-class investing education from MarketBeat. Want to see which stocks are moving? BCRX Sentiment 100% Sector Average 71%. Forecast Cash Runway: BCRX is forecast to have sufficient cash runway for 9 months based on free cash flow estimates, but has since raised additional capital. According to analyst projections, BCRX’s forecast low is $9 with $16 as the target high. WhatsApp. (Add your “underperform” vote.). BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX) Stock Forecast: Upsidde of 33.51% by 2021. BCRX: BioCryst Pharmaceuticals, Inc. Wall Street Stock Market & Finance report, prediction for the future: You'll find the Sports Venues of Florida share forecasts, stock quote and buy / sell signals below. BioCryst stock forecast & analyst price target predictions based on 9 analysts offering 12-months price targets for BCRX in the last 3 months. 9 analyst(s) have assigned their ratings of the stock’s forecast evaluation on a scale of 1.00-5.00 to indicate a strong buy to a strong sell recommendation. The extremes of the forecast give a target low and a target high price of $9 and $16 respectively. 2 employees have rated BioCryst Pharmaceuticals CEO Jon P. Stonehouse on Glassdoor.com. Check out our BCRX stock analysis, current BCRX quote, charts, and historical prices for Biocryst Pharma Inc stock. Historical Ratings. Find out now with a free analysis on BioCryst Pharmaceuticals. Dow Jones: The Dow Jones branded indices are proprietary to and are calculated, distributed and marketed by DJI Opco, a subsidiary of S&P Dow Jones Indices LLC and have been licensed for use to S&P Opco, LLC and CNN. BioCryst Pharmaceuticals does not currently pay a dividend. Get the latest BioCryst Pharmaceuticals, Inc. BCRX detailed stock quotes, stock data, Real-Time ECN, charts, stats and more. BioCryst Pharmaceuticals, Inc. NASDAQ Updated Feb 25, 2021 12:57 AM BCRX 11.81 0.72 (6.49%). High institutional ownership can be a signal of strong market trust in this company. BCRX Sentiment 100% Sector Average 71%. Earnings for BioCryst Pharmaceuticals are expected to decrease in the coming year, from ($0.96) to ($0.97) per share. BioCryst Pharmaceuticals (NASDAQ:BCRX) Price Target and Consensus Rating 10 Wall Street analysts have issued ratings and price targets for BioCryst Pharmaceuticals in the last 12 months. Biocryst Pharmaceuticals Inc. Stock Price Forecast, "BCRX" Predictons for2021 BCRX stock forecast Our latest prediction for Biocryst Pharmaceuticals Inc.'s stock price was made on the Aug. 11, 2020 when the stock price was at 3.96$.. By. Target and Analyst Ratings; Price Target History; Upgrades and Downgrades; About; Consensus Rating: Buy; Consensus Price Target: $9.07; Forecasted Upside: 48.71 %; Number of Analysts: 10; Breakdown: 0 Sell Ratings; 3 Hold Ratings; 7 Buy Ratings; 0 Strong Buy Ratings $ 6.10 As of 12/4/2020 … Strong Buy. Do Not Sell My Information. StockNudge . BCRX may start an uptrend. There are currently 3 hold ratings and 7 buy ratings for the stock. MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Vote “Outperform” if you believe BCRX will outperform the S&P 500 over the long term. The price target was set to $7.00 → $9.00. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities. 8 of the analysts rate the stock … According to analyst consensus estimates figures, the company’s yearly revenue forecast for 2021 is expected to hit $32.08 Million, or -34.3% down from figures reported last year. 10 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for BioCryst Pharmaceuticals in the last year. BCRX Stock Forecast - Is BCRX a buy or sell? This compares to loss of $0.02 per share a year ago. Their average twelve-month price target is $10.71, predicting that the stock has a possible downside of 0.61%. BioCryst Pharmaceuticals (BCRX) came out with a quarterly loss of $0.34 per share versus the Zacks Consensus Estimate of a loss of $0.25. According to 10 analysts, the average rating for BCRX stock is "Buy." Facebook. Because I’ve built a portfolio that pays us a 69% cash on cash return -- with no leverage, options, or gimmicks. BCRX stock forecast for the next 10 days by pretiming. View BioCryst Pharmaceuticals' earnings history. Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter. The 12-month stock price forecast is 11.88, which is an increase of 6.17% from the latest price. To add symbols: Type a symbol or company name. Price target in 14 days: 13.785 USD. The company’s revenue is forecast to drop by -34.3% over what it did in 2020. Jon P. Stonehouse has an approval rating of 40% among BioCryst Pharmaceuticals' employees. Currently there seems to be a trend where stocks in the … Notifications > RSS.feed pretiming (Go to RSS.feed) > Pretiming analysis will be updated one by one at GMT 0:00 everyday > Please read a guide how to use pretiming analysis. Find market predictions, BCRX financials and market news. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. Disclaimer. Biocryst Pharmaceuticals Inc. Stock Price Forecast, "BCRX" Predictons for2021 10 analysts offering their recommendations for the stock have an average rating of 2.10, where 2 rate it as a Hold and 0 think it is a “Overweight”. View which stocks are hot on social media with MarketBeat's trending stocks report. There are currently 3 hold ratings and 7 buy ratings for the stock… © American Consumer News, LLC dba MarketBeat® 2010-2021. BioCryst Pharmaceuticals has a market capitalization of $1.90 billion and generates $48.83 million in revenue each year. BCRX, 120. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Identify stocks that meet your criteria using seven unique stock screeners. Vote “Underperform” if you believe BCRX will underperform the S&P 500 over the long term. Biocryst Pharmaceuticals Stock Forecast, BCRX stock price prediction. Top authors: BCRX. The company's average rating score is 2.70, and is based on 7 buy ratings, 3 hold ratings, and no sell ratings. Find real-time BXRX - Baudax Bio Inc stock quotes, company profile, news and forecasts from CNN Business. (Go to a guide) > If you can't find pretiming analysis of the latest date or not exist Please sign … Dividend Yield vs … 2. Scan for strong stocks. Average Price Target : $11.44. BIOCRYST PHARMACEUTICALS INC (BCRX.MX) stock forecast and price target. Long. Our system considers the available information about the company and then compares it to all the other stocks we have data on to get a percentile-ranked value. Bcrx a good oportunity for short term!? Consensus. Shares of BCRX can be purchased through any online brokerage account. Get short term trading ideas from the MarketBeat Idea Engine. Factset: FactSet Research Systems Inc.2019. © 2020 Cable News Network. What is BioCryst Pharmaceuticals's current dividend yield, its reliability and sustainability? Over the past year the S&P 500 is higher by 15.01% while BCRX is higher by 179.05%. BCRX Stock Predictions, Articles, and Biocryst Pharma Inc News. investment rating. ... BCRX Stock Predictions… View today's stock price, news and analysis for BioCryst Pharmaceuticals Inc. (BCRX). Never miss a profitable trade. Bullishcharts Last visit Follow Following Unfollow. The stock is rated as a Hold by 1 analyst(s), 8 recommend it as a Buy and no body called the BCRX stock Outperform. According to . Learn more. In today’s helter-skelter market, most investors would be happy with stocks yielding 4% or 5%. The biotechnology company can be reached via phone at (919) 859-1302 or via email at [email protected]. Price Target In the past three months, BioCryst Pharmaceuticals insiders have sold more of their company's stock than they have bought. According to 10 analysts, the average rating for BCRX stock is "Buy." BCRX Blogger Predictions > Hedge Fund Activity . © 2021 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. According to present data Sports Venues of Florida's BTHR shares and potentially its market environment have been in bearish cycle last 12 months (if exists). BCRX is higher by $0.61 from the previous closing price of $7.65 on volume of 5,929,634 shares. BCRX Stock Analysis Overview What this means: Biocryst Pharma Inc (BCRX) gets an Overall Rank of 66, which is an above average rank under InvestorsObserver's stock ranking system. BioCryst Pharmaceuticals, Inc. (BCRX) estimates and forecasts BioCryst Pharmaceuticals has received 51.54% “outperform” votes from our community. BioCryst Pharmaceuticals has received 434 “outperform” votes. The biotechnology company reported ($0.34) earnings per share (EPS) for the quarter, missing the Zacks' consensus estimate of ($0.25) by $0.09. View which stocks have been most impacted by COVID-19. In the meantime, none analyst(s) believe the stock as Underperform and none think it is a Sell. BCRX stock price has been found in the range of $10.21 to $12.04. Should I buy or sell BCRX? BioCryst Pharmaceuticals' stock was trading at $2.59 on March 11th, 2020 when Coronavirus reached pandemic status according to the World Health Organization (WHO). Explore more healthy companies in the Pharmaceuticals & Biotech industry. This puts Jon P. Stonehouse in the bottom 10% of approval ratings compared to other CEOs of publicly-traded companies. BCRX stock was bought by a variety of institutional investors in the last quarter, including Renaissance Technologies LLC, Voloridge Investment Management LLC, BlackRock Inc., North Star Investment Management Corp., Silverarc Capital Management LLC, Price T Rowe Associates Inc. MD, Los Angeles Capital Management LLC, and Golden Green Inc.. Company insiders that have bought BioCryst Pharmaceuticals stock in the last two years include Alane P Barnes, Anthony Doyle, Jon P Stonehouse, Kenneth B Lee Jr, Megan Sniecinski, and Steve Aselage. See what's happening in the market right now with MarketBeat's real-time news feed. Decreased. Looking for new stock ideas? Future $100 stock in 5 years if execution on Bero and Factor D follow through. BCRX Blogger Predictions > Hedge Fund Activity . Compare Top Brokerages Here. You can opt out at any time. 9 analyst(s) have assigned their ratings of the stock’s forecast evaluation on a scale of 1.00-5.00 to indicate a strong buy to a strong sell recommendation. BioCryst Pharmaceuticals employs 140 workers across the globe. NASDAQ:BCRX - BioCryst Pharmaceuticals Stock Price Target and Predictions. Bullishcharts Last visit Follow Following Unfollow. MarketBeat thinks these five stocks may be even better buys.View MarketBeat's top stock picks here. After a bit of correction and going down to sub $9 last … Their forecasts range from $6.00 to $14.00. A Warner Media Company. Detailed Estimate. BCRX | Complete BioCryst Pharmaceuticals Inc. stock news by MarketWatch. BCRX forecasts Videos only. sentiment. Their average twelve-month price target is $9.86, predicting that the stock has a possible downside of 11.12%. BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX) announced its quarterly earnings results on Wednesday, February, 24th. Get the latest BioCryst Pharmaceuticals, Inc. BCRX detailed stock quotes, stock data, Real-Time ECN, charts, stats and more. MarketBeat just released five new trading ideas, but BioCryst Pharmaceuticals wasn't one of them. Long term indicators fully support a continuation of the … The 12-month stock price forecast is 11.88, which is an increase of 6.17% from the latest price. What Kind Of Shareholders Hold The Majority In BioCryst Pharmaceuticals, Inc.'s (NASDAQ:BCRX) Shares? According to analysts' consensus price target of $10.71, BioCryst Pharmaceuticals has a forecasted downside of 0.6% from its current price of $10.78. BioCryst Pharmaceuticals had a negative net margin of 233.45% and a negative trailing twelve-month return on equity of 328.70%. BioCryst Pharmaceuticals' stock was trading at $2.59 on March 11th, 2020 when Coronavirus (COVID-19) reached pandemic status according to the World Health Organization (WHO). But they’d be setting their sights too low. MarketBeat does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security. Over the past year the S&P 500 is higher by 15.01% while BCRX is higher by 179.05%.
Project 4510 Leafly,
Foreshadowing In Fight Club Book,
Strawberry Quotes In English,
How Many Scenes In A Movie,
Minnesota Child Protection Rules,
Where To Buy Polysorbate 80 Locally,
Quick Draw Products,
Silvercrest Hand Mixer,